TABLE 2.

Effects of the GluN2B and GluN2A antagonists at DIV 10.

(A) Pyramidal cells treated with ifenprodil/Ro25-6981 and TCN201/NVP-AAM077 from DIV 7–10
	Pyramidal cells of layers II/III		Pyramidal cells of layers V/VI
Condition (no. of batches)	ADL (n) Segments	BDL Segments	ADL (n) Segments	BDL Segments
Control	1167 ± 50 (89) 32 ± 1.5	244 ± 13 7.0 ± 0.4	1016 ± 37 (75) 23 ± 1.2	272 ± 14 6.8 ± 0.3
Ifenprodil/Ro25-6981 (3 each)	1041 ± 40 (49/38) 28 ± 1.2	194 ± 8.1 5.8 ± 0.3	1000 ± 43 (37/40) 22 ± 1.1	207 ± 10 5.5 ± 0.3
Mann–Whitney test vs. control	P = 0.1 P = 0.06	P = 0.014 P = 0.026	P = 0.41 P = 0.58	P < 0.001 P = 0.004
Control	1193 ± 48 (101) 32 ± 1.3	237 ± 11 6.9 ± 0.3	1014 ± 39 (64) 22 ± 1.2	269 ± 14 7.1 ± 0.4
TCN201/NVP-AAM077 (2 and 3)	1121 ± 40 (25/60) 31 ± 1.3	229 ± 9 7.0 ± 0.3	1056 ± 42 (18/49) 24 ± 1.1	253 ± 14 6.6 ± 0.4
Mann–Whitney test vs. control	P = 0.56 P = 0.86	P = 0.95 P = 0.6	P = 0.51 P = 0.15	P = 0.36 P = 0.3
(B) Interneurons treated with ifenprodil/Ro25-6981 and TCN201/NVP-AAM077 from DIV 7–10
Condition (no. of batches)	MDL (n)		MDS	No. of PD
Control	387 ± 17 (111)		7.0 ± 0.3	4.5 ± 0.1
Ifenprodil/Ro25-6981 (3 each)	352 ± 16 (56/37)		7.1 ± 0.4	4.6 ± 0.2
Mann–Whitney test vs. control	P = 0.14		P = 0.5	P = 0.6
Control	401 ± 26 (69)		6.4 ± 0.4	4.7 ± 0.2
TCN201/NVP-AAM077 (2 and 3)	395 ± 21 (18/58)		7.3 ± 0.4	4.6 ± 0.2
Mann–Whitney test vs. control	P = 0.78		P = 0.1	P = 0.83

Antagonists were applied at DIV 7 and DIV 9. Given is the mean ± S.E.M, and, in italics, the p-values of the Mann–Whitney rank sum test. For pyramidal cells in (A): ADL, apical dendritic length [μm]; BDL, the average basal dendritic length per cell [μm]; the number of dendritic segments; for interneurons in (B): MDL, mean dendritic length [μm] per cell; MDS, mean dendritic segments; no. of PD, number of primary dendrites; n, number of neurons analyzed. In bold, the parameters that differ significantly from control.